Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-40
SponsorAdventHealth Translational Research Institute
About this trial
The investigators will test the hypothesis that, in adults with type 1 diabetes (T1D), glucagon-like peptide-1 receptor agonism (GLP-1RA, i.e. dulaglutide) enhances insulin-mediated skeletal muscle microvascular perfusion via attenuating endothelial oxidative stress and thereby improving endothelial function.
Eligibility criteria
Qualifiers
History of type 1 diabetes, duration > 5 years
Age 18-40 years
HbA1c < 8.5%
BMI 19-34.9 kg/m2
Disqualifiers
Pregnancy or currently breastfeeding
Smoking history within 6 months
History of microvascular (microalbuminuria, retinopathy, neuropathy) or macrovascular diabetes complications (coronary artery disease, stroke, peripheral vascular disease) as well as clinically significant cardiac arrhythmias or conduction disorders
Taking vasoactive medications (i.e. calcium channel blockers, angiotensin-converting enzyme or renin inhibitors, angiotensin-receptor blockers, nitrates, alpha-blockers).
Trial design
Treatments tested in this trial
- Dulaglutide
- Placebo
Treatment groups
47 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov